MUMBAI, India, Aug. 17 -- Intellectual Property India has published a patent application (202641096627 A) filed by Vellore Institute Of Technology on August 10, 2026, for Nebulized Nanoemulsion Formulation For Targeted Pulmonary Delivery Of Antituberculosis Drugs.
Inventors include Natarajan Chandrasekaran; Dr. George Priya Doss C; and Dr. Mohanraj Gopikrishnan.
The application for the patent was published on August 14, 2026, under issue no. 33/2026.
Abstract: The present invention relates to a nebulized nanoemulsion formulation and system for targeted pulmonary delivery of antituberculosis drugs. The formulation comprises a eugenol-based oil phase, Tween 80 as a surfactant, and an aqueous phase, wherein a lipophilic drug, rifampicin, is encapsulated within the oil phase, while hydrophilic drugs including isoniazid, pyrazinamide, and ethambutol are incorporated into the aqueous phase. The nanoemulsion is prepared using a water titration method followed by high-pressure homogenization to obtain a stable formulation having nanosized droplets suitable for nebulization. The formulation is administered through a nebulizer to generate respirable aerosols capable of deep-lung deposition. Aerodynamic performance and particle deposition characteristics are validated using a Next Generation Impactor (NGI). The invention enhances localized pulmonary drug delivery, improves bioavailability and therapeutic efficacy, reduces systemic toxicity, and increases patient compliance in the treatment of pulmonary tuberculosis.
Disclaimer: Curated by HT Syndication.
